Related Experiment Video

Updated: Aug 21, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

A hard look at angiotensin receptor blockers in heart failure

Christian N Gring1, Gary S Francis

  • 1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. gringc@ccf.org

Journal of the American College of Cardiology
|November 3, 2004
PubMed

Insights

Angiotensin receptor blockers (ARBs) are not first-line for left ventricular dysfunction. ACE inhibitors are preferred, with ARBs reserved for ACE-intolerant patients or combination therapy in select heart failure cases.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin receptor blockers (ARBs) have been studied for left ventricular dysfunction post-myocardial infarction and in chronic heart failure.
  • Confusion persists regarding ARB efficacy as monotherapy and indications for combination therapy with ACE inhibitors.

Purpose of the Study:

  • To clarify the role of ARBs, alone or in combination with ACE inhibitors, for left ventricular dysfunction.
  • To analyze key trial differences influencing ARB and ACE inhibitor therapy recommendations.

Main Methods:

  • Review and analysis of multiple clinical trials on ARBs and ACE inhibitors.
  • Comparison of trial parameters: ACE inhibitor dose, ARB type and dose, blood pressure reduction, and patient populations.

Main Results:

  • Angiotensin-converting enzyme (ACE) inhibitors are established as first-line therapy for left ventricular dysfunction.
  • ARBs are recommended for monotherapy in patients intolerant to ACE inhibitors.
  • Combination ARB/ACE inhibitor therapy is indicated for symptomatic patients with chronic heart failure (Class II/III).

Conclusions:

  • ACE inhibitors remain the cornerstone of treatment for left ventricular dysfunction.
  • Strategic use of ARBs is crucial for specific patient subsets, including ACE-intolerant individuals and those with persistent symptoms despite ACE inhibition.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...